It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Targeted contact-tracing through mobile phone apps has been proposed as an instrument to help contain the spread of COVID-19 and manage the lifting of nation-wide lock-downs currently in place in USA and Europe. However, there is an ongoing debate on its potential efficacy, especially in light of region-specific demographics. We built an expanded SIR model of COVID-19 epidemics that accounts for region-specific population densities, and we used it to test the impact of a contact-tracing app in a number of scenarios. Using demographic and mobility data from Italy and Spain, we used the model to simulate scenarios that vary in baseline contact rates, population densities, and fraction of app users in the population. Our results show that, in support of efficient isolation of symptomatic cases, app-mediated contact-tracing can successfully mitigate the epidemic even with a relatively small fraction of users, and even suppress altogether with a larger fraction of users. However, when regional differences in population density are taken into consideration, the epidemic can be significantly harder to contain in higher density areas, highlighting potential limitations of this intervention in specific contexts. This work corroborates previous results in favor of app-mediated contact-tracing as mitigation measure for COVID-19, and draws attention on the importance of region-specific demographic and mobility factors to achieve maximum efficacy in containment policies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Papa Giovanni XXIII Hospital, FROM Research Foundation, Bergamo, Italy (GRID:grid.460094.f) (ISNI:0000 0004 1757 8431)
2 Bayer, Decision Science & Advanced Analytics for MA, PV & RA Division, Leverkusen, Germany (GRID:grid.420044.6) (ISNI:0000 0004 0374 4101)
3 Barcelona Supercomputing Center (BSC), Barcelona, Spain (GRID:grid.10097.3f) (ISNI:0000 0004 0387 1602); Women’s Brain Project (WBP), Gunterhausen, Switzerland (GRID:grid.508244.f)
4 Barcelona Supercomputing Center (BSC), Barcelona, Spain (GRID:grid.10097.3f) (ISNI:0000 0004 0387 1602)
5 Women’s Brain Project (WBP), Gunterhausen, Switzerland (GRID:grid.508244.f); Universitá di Foggia Chirurgiche, Dipartimento di Scienze Madiche e, Foggia, Italy (GRID:grid.10796.39) (ISNI:0000000121049995)
6 Women’s Brain Project (WBP), Gunterhausen, Switzerland (GRID:grid.508244.f)
7 Women’s Brain Project (WBP), Gunterhausen, Switzerland (GRID:grid.508244.f); Interactive Robots and Media Laboratory (IRLM), Abu Dhabi, United Arab Emirates (GRID:grid.508244.f)
8 Barcelona Supercomputing Center (BSC), Barcelona, Spain (GRID:grid.10097.3f) (ISNI:0000 0004 0387 1602); ICREA, Barcelona, Spain (GRID:grid.425902.8) (ISNI:0000 0000 9601 989X)